Nanomedicine (London, England) · 2015
Developing cutaneous applications of paromomycin entrapped in stimuli-sensitive block copolymer nanogel dispersions.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brugués Alba Pujol, Naveros Beatriz Clares, Calpena Campmany Ana C, Pastor Pilar Hernández, Saladrigas Roser Fisa, Lizandra Cristina Riera
Аннотация
AIM: A new paromomycin micellar nanogel based on poloxamer 407 was developed.
MATERIALS & METHODS: In vitro release and ex vivo permeation/retention studies were conducted. In vivo tolerance was assayed by transepidermal water loss. Ex vivo cytotoxicity on RAW and VERO cells and antileishmanial activity on Leishmania promastigotes was tested.
RESULTS: The particle size was 9.19 nm (99% loading efficiency) exhibiting Newtonian behavior at 4°C and was pseudoplastic at 25 and 40°C. Drug release followed a Weibull model and the drug remaining in the skin was 31.652 µg/g/cm(2). In vivo tolerance achieved excellent results with negligible cellular toxicity and the best antileishmanial efficiency.
CONCLUSION: The nanogel provided controlled, effective and safe delivery of paromomycin for the treatment of cutaneous leishmaniasis.
MATERIALS & METHODS: In vitro release and ex vivo permeation/retention studies were conducted. In vivo tolerance was assayed by transepidermal water loss. Ex vivo cytotoxicity on RAW and VERO cells and antileishmanial activity on Leishmania promastigotes was tested.
RESULTS: The particle size was 9.19 nm (99% loading efficiency) exhibiting Newtonian behavior at 4°C and was pseudoplastic at 25 and 40°C. Drug release followed a Weibull model and the drug remaining in the skin was 31.652 µg/g/cm(2). In vivo tolerance achieved excellent results with negligible cellular toxicity and the best antileishmanial efficiency.
CONCLUSION: The nanogel provided controlled, effective and safe delivery of paromomycin for the treatment of cutaneous leishmaniasis.